Aim: EAs with T1D may benefit from innovative diabetes treatments, given their challenges in meeting glycemic targets. Thus, a measure of self-management responsive to newer regimens is important for this population. In this study, performance of the DMQ, initially validated in 8-18 year olds, was evaluated in EAs.

Methods: EAs (ages 18-25) with T1D completed an online study, providing demographic and diabetes management data along with survey responses. Surveys included DMQ, RISQ (measure of self-care readiness), and PAID-EA (measure of diabetes distress in EAs). The 20-item DMQ assesses self-care over the past month with response options on a 5-point Likert scale. Total scores range from 0-100; higher scores indicate greater self-management. We assessed internal consistency (Cronbach’s alpha, item-to-total correlations) and concurrent validity of the DMQ.

Results: The sample of 141 EAs (30% male, 61% female, 9% trans/non-binary) had mean age 21.5 ± 2.2 years and T1D duration 12.2 ± 5.4 years; 84% were non-Hispanic white and 57% were students. Self-reported A1c was 7.3 ± 0.9%; 93% used CGM, 79% used a pump, and 68% used AID. DMQ Cronbach’s α was 0.86. Item-to-total correlations were all >0.2 aside from 1 item regarding ketone monitoring. DMQ scores were inversely correlated with A1c (r=-.26, p<.01), and diabetes distress (PAID-EA, r=-.26, p<.01), and positively correlated with CGM TIR (r=.22, p=.02) and self-care readiness (RISQ, r=.36, p<.01). DMQ did not correlate with age (p=.27) or T1D duration (p=.19). DMQ-EA scores did not differ by pump use (p=.99) or gender (p=.05), but scores were higher among CGM users than non-users (74 vs. 60, p<.01).

Conclusion: The DMQ, completed in <5 minutes, demonstrated strong psychometric properties as a measure of self-care in EAs with T1D. An up-to-date adherence survey that performs well in emerging adults using advanced diabetes technologies offers measurement opportunities in research and clinical settings.

Disclosure

R.J. Vitale: None. L.J. Tinsley: None. L.K. Volkening: None. K. Garvey: Advisory Panel; Sanofi. L.M. Laffel: Consultant; Dexcom, Inc. Advisory Panel; Medscape, Medtronic, Vertex Pharmaceuticals Incorporated. Consultant; Novo Nordisk. Advisory Panel; Lilly Diabetes, Provention Bio, Inc., Sanofi-Aventis U.S., Janssen Pharmaceuticals, Inc., MannKind Corporation.

Funding

Endocrine Fellows Foundation; NIH (T32DK007529NIH P30DK036836); Iacocca Foundation Senior Postdoctoral Fellowship

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.